Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Information Dissemination | 15 | 2024 | 200 | 5.050 |
Why?
|
| Informed Consent | 9 | 2024 | 346 | 1.810 |
Why?
|
| Bioethics | 6 | 2020 | 74 | 1.460 |
Why?
|
| Databases, Genetic | 3 | 2019 | 502 | 1.420 |
Why?
|
| Health Care Rationing | 2 | 2024 | 63 | 1.270 |
Why?
|
| Confidentiality | 5 | 2019 | 106 | 1.140 |
Why?
|
| Public Policy | 6 | 2016 | 54 | 1.100 |
Why?
|
| Medical Informatics | 5 | 2019 | 110 | 1.080 |
Why?
|
| Genetic Testing | 8 | 2024 | 1099 | 1.070 |
Why?
|
| Ethics Committees, Clinical | 3 | 2024 | 18 | 1.040 |
Why?
|
| Stakeholder Participation | 4 | 2025 | 32 | 1.010 |
Why?
|
| Health Equity | 2 | 2024 | 75 | 0.970 |
Why?
|
| Ethics Committees | 1 | 2024 | 3 | 0.910 |
Why?
|
| Charities | 1 | 2024 | 4 | 0.910 |
Why?
|
| Uncompensated Care | 1 | 2024 | 12 | 0.900 |
Why?
|
| Resource Allocation | 1 | 2024 | 53 | 0.880 |
Why?
|
| Direct-To-Consumer Screening and Testing | 2 | 2022 | 14 | 0.850 |
Why?
|
| Privacy | 2 | 2021 | 28 | 0.820 |
Why?
|
| Embryo Research | 4 | 2009 | 9 | 0.750 |
Why?
|
| Genetic Research | 2 | 2019 | 56 | 0.710 |
Why?
|
| Computer Security | 2 | 2018 | 28 | 0.700 |
Why?
|
| Ethics Consultation | 4 | 2016 | 28 | 0.700 |
Why?
|
| Genetic Privacy | 2 | 2018 | 43 | 0.690 |
Why?
|
| Mentoring | 1 | 2022 | 83 | 0.670 |
Why?
|
| Genetics | 1 | 2020 | 24 | 0.660 |
Why?
|
| Patents as Topic | 2 | 2017 | 19 | 0.660 |
Why?
|
| Scholarly Communication | 1 | 2020 | 7 | 0.650 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 330 | 0.650 |
Why?
|
| Mentors | 1 | 2022 | 164 | 0.650 |
Why?
|
| Ethics, Clinical | 2 | 2022 | 77 | 0.640 |
Why?
|
| Biomedical Research | 4 | 2019 | 554 | 0.640 |
Why?
|
| Embryonic Stem Cells | 3 | 2009 | 167 | 0.630 |
Why?
|
| Humans | 61 | 2025 | 132247 | 0.620 |
Why?
|
| Biomedical Technology | 1 | 2019 | 36 | 0.590 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 73 | 0.590 |
Why?
|
| Personally Identifiable Information | 1 | 2018 | 1 | 0.590 |
Why?
|
| Genotype | 1 | 2024 | 2703 | 0.570 |
Why?
|
| Mental Health | 1 | 2021 | 377 | 0.550 |
Why?
|
| Schools | 1 | 2019 | 236 | 0.540 |
Why?
|
| Ethicists | 4 | 2022 | 46 | 0.540 |
Why?
|
| Parents | 4 | 2024 | 1080 | 0.540 |
Why?
|
| Health Policy | 2 | 2019 | 232 | 0.530 |
Why?
|
| Public Health | 1 | 2019 | 280 | 0.530 |
Why?
|
| United States | 19 | 2021 | 11669 | 0.530 |
Why?
|
| Homocysteine | 1 | 2017 | 120 | 0.530 |
Why?
|
| Patients | 3 | 2018 | 129 | 0.520 |
Why?
|
| Physician-Patient Relations | 3 | 2024 | 447 | 0.520 |
Why?
|
| Autistic Disorder | 1 | 2020 | 387 | 0.500 |
Why?
|
| Federal Government | 1 | 2016 | 19 | 0.490 |
Why?
|
| Communication | 3 | 2018 | 541 | 0.490 |
Why?
|
| Public Opinion | 1 | 2016 | 62 | 0.490 |
Why?
|
| Minors | 1 | 2015 | 4 | 0.490 |
Why?
|
| Clinical Medicine | 1 | 2016 | 22 | 0.480 |
Why?
|
| Internationality | 1 | 2016 | 133 | 0.480 |
Why?
|
| Parental Consent | 1 | 2015 | 22 | 0.480 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 160 | 0.470 |
Why?
|
| Research Subjects | 1 | 2015 | 54 | 0.470 |
Why?
|
| Decision Making | 4 | 2024 | 699 | 0.460 |
Why?
|
| Physician's Role | 2 | 2024 | 168 | 0.460 |
Why?
|
| Moral Obligations | 2 | 2013 | 76 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.450 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2009 | 135 | 0.450 |
Why?
|
| Advisory Committees | 4 | 2009 | 151 | 0.440 |
Why?
|
| Quality Improvement | 1 | 2020 | 700 | 0.430 |
Why?
|
| Vaccination | 1 | 2019 | 1018 | 0.430 |
Why?
|
| Internship and Residency | 1 | 2024 | 1258 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 946 | 0.420 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1096 | 0.410 |
Why?
|
| Disclosure | 4 | 2024 | 153 | 0.400 |
Why?
|
| Blood Glucose | 1 | 2017 | 1121 | 0.400 |
Why?
|
| Truth Disclosure | 1 | 2014 | 105 | 0.390 |
Why?
|
| Fear | 1 | 2014 | 205 | 0.380 |
Why?
|
| Pandemics | 1 | 2020 | 1186 | 0.380 |
Why?
|
| Policy Making | 2 | 2019 | 62 | 0.380 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 127 | 0.380 |
Why?
|
| Treatment Refusal | 1 | 2013 | 80 | 0.380 |
Why?
|
| Ventricular Function | 1 | 2013 | 91 | 0.380 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 152 | 0.370 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2012 | 9 | 0.370 |
Why?
|
| Neurosciences | 2 | 2024 | 52 | 0.370 |
Why?
|
| Fetal Viability | 1 | 2012 | 30 | 0.370 |
Why?
|
| Preimplantation Diagnosis | 1 | 2012 | 27 | 0.360 |
Why?
|
| Genomics | 7 | 2024 | 1652 | 0.360 |
Why?
|
| Guidelines as Topic | 2 | 2009 | 196 | 0.350 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1161 | 0.340 |
Why?
|
| Oncologists | 2 | 2023 | 31 | 0.340 |
Why?
|
| Neoplasms | 5 | 2024 | 2961 | 0.340 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 161 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1803 | 0.320 |
Why?
|
| Algorithms | 1 | 2017 | 1725 | 0.320 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 311 | 0.310 |
Why?
|
| Patient Discharge | 1 | 2014 | 511 | 0.310 |
Why?
|
| Government Regulation | 1 | 2009 | 43 | 0.300 |
Why?
|
| Information Technology | 2 | 2019 | 9 | 0.300 |
Why?
|
| Chimera | 1 | 2009 | 83 | 0.300 |
Why?
|
| Patient Selection | 1 | 2013 | 731 | 0.300 |
Why?
|
| Community Participation | 2 | 2019 | 42 | 0.290 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 75 | 0.290 |
Why?
|
| Social Responsibility | 3 | 2024 | 84 | 0.280 |
Why?
|
| Patient Participation | 4 | 2023 | 240 | 0.280 |
Why?
|
| Ethical Analysis | 2 | 2019 | 48 | 0.270 |
Why?
|
| Physicians | 2 | 2018 | 640 | 0.270 |
Why?
|
| Social Justice | 2 | 2024 | 65 | 0.260 |
Why?
|
| Heart-Assist Devices | 2 | 2013 | 1085 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1418 | 0.260 |
Why?
|
| Embryo, Mammalian | 2 | 2009 | 441 | 0.260 |
Why?
|
| Policy | 2 | 2024 | 37 | 0.250 |
Why?
|
| Autopsy | 2 | 2016 | 120 | 0.250 |
Why?
|
| Ethics, Medical | 4 | 2016 | 401 | 0.240 |
Why?
|
| Bioethical Issues | 1 | 2005 | 23 | 0.240 |
Why?
|
| Cybernetics | 1 | 2005 | 1 | 0.230 |
Why?
|
| Embryo Disposition | 1 | 2005 | 1 | 0.230 |
Why?
|
| Legislation, Medical | 1 | 2005 | 13 | 0.230 |
Why?
|
| Adoption | 1 | 2005 | 18 | 0.230 |
Why?
|
| Expert Testimony | 1 | 2005 | 36 | 0.220 |
Why?
|
| Managed Care Programs | 1 | 2005 | 56 | 0.220 |
Why?
|
| Embryo Transfer | 1 | 2005 | 56 | 0.220 |
Why?
|
| Hospitals, Voluntary | 1 | 2004 | 5 | 0.220 |
Why?
|
| Goals | 1 | 2005 | 134 | 0.220 |
Why?
|
| Biological Specimen Banks | 1 | 2005 | 55 | 0.220 |
Why?
|
| Professional Role | 1 | 2005 | 73 | 0.220 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2024 | 13 | 0.210 |
Why?
|
| Insurance Benefits | 1 | 2004 | 4 | 0.210 |
Why?
|
| Stem Cells | 1 | 2009 | 733 | 0.210 |
Why?
|
| Ecosystem | 1 | 2024 | 107 | 0.210 |
Why?
|
| Medically Uninsured | 1 | 2004 | 78 | 0.210 |
Why?
|
| Neurophysiology | 1 | 2023 | 19 | 0.210 |
Why?
|
| HIV Infections | 1 | 2015 | 2049 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2005 | 232 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2004 | 187 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2004 | 144 | 0.200 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2022 | 18 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2004 | 127 | 0.190 |
Why?
|
| Health Insurance Portability and Accountability Act | 2 | 2017 | 21 | 0.190 |
Why?
|
| Bangladesh | 2 | 2022 | 35 | 0.190 |
Why?
|
| General Surgery | 1 | 2024 | 227 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 409 | 0.180 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2021 | 13 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 3995 | 0.180 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 139 | 0.170 |
Why?
|
| Genetic Counseling | 2 | 2022 | 246 | 0.170 |
Why?
|
| RNA | 1 | 2024 | 552 | 0.170 |
Why?
|
| Surgeons | 1 | 2024 | 286 | 0.160 |
Why?
|
| Coroners and Medical Examiners | 2 | 2016 | 15 | 0.160 |
Why?
|
| Ownership | 1 | 2019 | 35 | 0.160 |
Why?
|
| Heart Failure | 1 | 2013 | 2398 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 564 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 325 | 0.140 |
Why?
|
| Military Personnel | 1 | 2020 | 203 | 0.140 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 48 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 60 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| Hospital Administrators | 1 | 2016 | 8 | 0.120 |
Why?
|
| State Government | 1 | 2015 | 30 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2015 | 53 | 0.120 |
Why?
|
| Professional Competence | 2 | 2014 | 96 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 95 | 0.110 |
Why?
|
| Radiation Oncology | 1 | 2014 | 28 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3358 | 0.110 |
Why?
|
| Politics | 2 | 2005 | 62 | 0.110 |
Why?
|
| Cadaver | 2 | 2016 | 119 | 0.110 |
Why?
|
| Orbital Neoplasms | 1 | 2014 | 48 | 0.110 |
Why?
|
| Female | 9 | 2024 | 70787 | 0.110 |
Why?
|
| Licensure | 1 | 2014 | 15 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 145 | 0.110 |
Why?
|
| Exome | 1 | 2018 | 1087 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 846 | 0.100 |
Why?
|
| Forecasting | 2 | 2019 | 373 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 72 | 0.100 |
Why?
|
| Writing | 1 | 2014 | 66 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3761 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 462 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 899 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2014 | 306 | 0.090 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 725 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 2014 | 215 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3194 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2013 | 213 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 20557 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 463 | 0.080 |
Why?
|
| Research Embryo Creation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Male | 8 | 2024 | 65014 | 0.080 |
Why?
|
| Ethics Committees, Research | 1 | 2009 | 32 | 0.080 |
Why?
|
| Financing, Government | 1 | 2009 | 32 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2009 | 62 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 674 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2009 | 55 | 0.070 |
Why?
|
| Adult | 7 | 2024 | 31614 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 249 | 0.070 |
Why?
|
| Risk Factors | 2 | 2022 | 10945 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 246 | 0.060 |
Why?
|
| Quality of Life | 2 | 2013 | 2161 | 0.060 |
Why?
|
| Committee Membership | 1 | 2005 | 3 | 0.060 |
Why?
|
| Dissent and Disputes | 1 | 2005 | 32 | 0.060 |
Why?
|
| Publications | 1 | 2005 | 35 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 503 | 0.060 |
Why?
|
| Biotechnology | 1 | 2005 | 59 | 0.060 |
Why?
|
| Contract Services | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lawyers | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ethics, Institutional | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2005 | 70 | 0.060 |
Why?
|
| Fees and Charges | 1 | 2004 | 11 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2681 | 0.050 |
Why?
|
| DNA | 1 | 2010 | 1479 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 13049 | 0.050 |
Why?
|
| Cell Line | 1 | 2009 | 2724 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 157 | 0.050 |
Why?
|
| Prejudice | 1 | 2004 | 38 | 0.050 |
Why?
|
| Atrophy | 1 | 2024 | 251 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2004 | 141 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 9966 | 0.050 |
Why?
|
| Research | 1 | 2005 | 266 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 3632 | 0.050 |
Why?
|
| Research Personnel | 1 | 2024 | 136 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2022 | 116 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 83 | 0.050 |
Why?
|
| Phosphates | 1 | 2022 | 114 | 0.050 |
Why?
|
| Exploratory Behavior | 1 | 2022 | 55 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 576 | 0.040 |
Why?
|
| Child | 4 | 2024 | 25783 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 413 | 0.040 |
Why?
|
| Family | 1 | 2024 | 595 | 0.040 |
Why?
|
| Intellectual Property | 1 | 2019 | 9 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 67 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7557 | 0.040 |
Why?
|
| California | 1 | 2019 | 140 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 120 | 0.040 |
Why?
|
| Trust | 1 | 2019 | 82 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 96 | 0.040 |
Why?
|
| Pedigree | 1 | 2022 | 1724 | 0.040 |
Why?
|
| Information Services | 1 | 2017 | 22 | 0.030 |
Why?
|
| Calcium | 1 | 2022 | 1080 | 0.030 |
Why?
|
| Middle Aged | 4 | 2019 | 29021 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 244 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 13027 | 0.030 |
Why?
|
| Consent Forms | 1 | 2016 | 22 | 0.030 |
Why?
|
| Prevalence | 1 | 2022 | 2664 | 0.030 |
Why?
|
| Death | 1 | 2016 | 79 | 0.030 |
Why?
|
| Health Facility Merger | 1 | 2015 | 8 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 408 | 0.030 |
Why?
|
| Social Media | 1 | 2017 | 120 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 104 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 45 | 0.030 |
Why?
|
| North America | 1 | 2014 | 265 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 94 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3736 | 0.010 |
Why?
|
| Consultants | 1 | 2005 | 11 | 0.010 |
Why?
|
| Hospital Administration | 1 | 2005 | 25 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2005 | 67 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8548 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 14736 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 21482 | 0.010 |
Why?
|